Amphastar Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 11, 2023 (filed September 15, 2023), details a material definitive agreement entered into by Amphastar Pharmaceuticals, Inc. (the "Company"). The filing reports the execution of a Purchase Agreement and the subsequent pricing of a convertible debt offering.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued $345.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2029. This includes an initial $300.0 million plus a full exercise of a $45.0 million option by initial purchasers.
- Net Proceeds: Approximately $333.9 million, after deducting discounts, commissions, and estimated offering expenses.
- Interest Rate: 2.00% per annum, payable semiannually in arrears beginning March 15, 2024.
- Maturity Date: March 15, 2029.
- Conversion Terms: Initial conversion rate of 15.8821 shares per $1,000 principal amount (approx. $62.96 per share), representing a 35.0% premium to the stock price on September 12, 2023.
- Use of Proceeds:
- $200.0 million used to repay borrowings under the Wells Fargo Credit Facility.
- $50.0 million used to repurchase common stock in privately negotiated transactions.
- Remainder designated for general corporate purposes, including potential acquisitions, working capital, and capital expenditures.
Material Changes and Liquidity Impact
The transaction significantly alters the Company's capital structure by adding $345.0 million in senior unsecured debt. Concurrently, the Company reduced its existing indebtedness by $200.0 million through the repayment of the Wells Fargo Credit Facility. The filing does not provide specific comparative financial metrics (e.g., revenue, profit, or cash flow) for the period, as this is a transactional filing rather than a periodic financial report.
Outlook, Risks, and Contingencies
- Redemption Rights: The Company may not redeem the Notes prior to September 21, 2026. After this date, redemption is permitted if the common stock price exceeds 130% of the conversion price for a specified period.
- Conversion Mechanics: Holders may convert notes under specific conditions prior to December 15, 2028, or at any time thereafter. Upon conversion, the Company may settle the obligation in cash, stock, or a combination.
- Events of Default: Includes failure to pay interest or principal, failure to convert upon exercise, bankruptcy, and cross-defaults on other indebtedness exceeding $50.0 million.
- Strategic Intent: Proceeds support the acquisition of BAQSIMI (glucagon) nasal powder and general corporate flexibility.
Investor Verification Checklist
- Verify the full text of the Indenture (Exhibit 4.1) for specific covenants and adjustment mechanisms regarding the conversion rate.
- Confirm the exact amount of remaining debt under the Wells Fargo Credit Facility post-repayment.
- Review the impact of the $50.0 million stock repurchase on the Company's outstanding share count and cash position.
- Monitor the Company's stock price relative to the $62.96 conversion price to assess the likelihood of conversion or redemption.
- Check for any subsequent filings regarding the status of the BAQSIMI acquisition milestone payments.